Comparison · NCT04023526-sae
Cusatuzumab 10 mg/kg Plus Azacitdine vs Cusatuzumab 20 mg/kg Plus Azacitidine: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cusatuzumab 10 mg/kg Plus Azacitdine vs Cusatuzumab 20 mg/kg Plus Azacitidine: serious adverse events. Trial comparisons, record NCT04023526-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04023526-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.863 | 0.743 | 0.932 | wilson | |
| Risk in group 2 | 0.784 | 0.654 | 0.875 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0784 | -0.072 | 0.226 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.1 | 0.918 | 1.32 | log | |
| Odds ratio, group 1 over group 2 | 1.73 | 0.611 | 4.89 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Cusatuzumab 10 mg/kg Plus Azacitdine than on Cusatuzumab 20 mg/kg Plus Azacitidine | 12.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cusatuzumab 10 mg/kg Plus Azacitdine | Participants received azacitidine 75 milligram per meter square (mg/m\^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle.~. | 44 | 51 | EG000 |
| Group 2 | Cusatuzumab 20 mg/kg Plus Azacitidine | Participants will receive azacitidine 75 mg/m\^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle. | 40 | 51 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first dose of study treatment at study day 1 until 30 days after the last dose of study intervention or until the start of subsequent anti-AML therapy (up to approximately 3 years and 5 months)
Source ClinicalTrials.gov
Trial
- Title
- A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
- NCT number
- NCT04023526
- Phases
- PHASE2
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Azacitidine, Cusatuzumab
- Lead sponsor
- OncoVerity, Inc.
- Results first posted
- 2024-07-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04023526?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04023526-sae